Micreos

This biotechnology company develops engineered endolysins, a class of precision biologics designed to selectively eliminate disease-driving pathogens while preserving healthy bacteria. Its lead program targets Staphylococcus aureus to treat Atopic Dermatitis, with additional research applications in oncology and infectious diseases. The company utilizes a proprietary platform to create protein-based antimicrobials that address antibiotic resistance and microbial imbalances.